Mario Mercuri

TL;DR: The state of the art of treatment for bone osteosarcoma in the pediatric age is reviewed, with the most effective drugs still the same as those employed over the last 20 years as front line neoadjuvant or adjuvant chemotherapy: Doxorubicin, Cisplatin, Methotrexate, Ifosfamide.

TL;DR: The evaluation variables influencing systemic and local recurrence and final outcome are extremely important in defining risk‐adapted treatments for patients with nonmetastatic osteosarcoma of the extremity.

TL;DR: There are five primary modes of endoprosthetic failure, and their relative incidences are significantly different and dependent on anatomic location.

TL;DR: Results showed that PRP induced SSC proliferation, and cells expanded with 10% PRP can mineralize the extracellular matrix once PRP is withdrawn, which is sufficient to induce a marked cell proliferation.

TL;DR: The addition of high- dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosFamide.